Paper3000292
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
Wolfson JS and 1 other. Antimicrob Agents Chemother, 1985. Cited by 666 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Papers, record 3000292. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3000292
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Bacteria | Major topic |
| Quinolines | Major topic |
| Chemical Phenomena | |
| Chemistry | |
| Drug Resistance, Microbial | |
| Structure-Activity Relationship | |
| Topoisomerase II Inhibitors |
Source PubMed
References76
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6,236,748 | In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6236748 | PubMed |
| 2 | 6,586,712 | In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. | J Antimicrob Chemother | 1984 | https://conductscience.org/library/papers/6586712 | PubMed |
| 3 | 6,234,858 | Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6234858 | PubMed |
| 4 | 6,203,890 | Investigations into the mechanism of action of the antibacterial agent norfloxacin. | J Antimicrob Chemother | 1984 | https://conductscience.org/library/papers/6203890 | PubMed |
| 5 | 6,098,219 | Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6098219 | PubMed |
| 6 | 6,721,464 | In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6721464 | PubMed |
| 7 | 6,383,207 | Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6383207 | PubMed |
| 8 | 4,895,844 | Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. | J Bacteriol | 1969 | https://conductscience.org/library/papers/4895844 | PubMed |
| 9 | 3,970,478 | The quinolones. | Ann Intern Med | 1985 | https://conductscience.org/library/papers/3970478 | PubMed |
| 10 | 6,222,695 | In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6222695 | PubMed |
| 11 | 16,559,090 | Nalidixic Acid and the Metabolism of Escherichia coli. | J Bacteriol | 1970 | https://conductscience.org/library/papers/16559090 | PubMed |
| 12 | 6,232,895 | Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6232895 | PubMed |
| 13 | 6,271,730 | New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. | J Bacteriol | 1981 | https://conductscience.org/library/papers/6271730 | PubMed |
| 14 | 6,097,803 | Biology of bacterial deoxyribonucleic acid topoisomerases. | Microbiol Rev | 1984 | https://conductscience.org/library/papers/6097803 | PubMed |
| 15 | 7,452,690 | Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. | J Med Chem | 1980 | https://conductscience.org/library/papers/7452690 | PubMed |
| 16 | 6,227,484 | In vitro activity of norfloxacin against Mycoplasma hominis and Ureaplasma urealyticum. | Eur J Clin Microbiol | 1983 | https://conductscience.org/library/papers/6227484 | PubMed |
| 17 | 6,240,224 | In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6240224 | PubMed |
| 18 | 6,422,043 | Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent. | J Med Chem | 1984 | https://conductscience.org/library/papers/6422043 | PubMed |
| 19 | 3,156,026 | Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin. | Chemotherapy | 1985 | https://conductscience.org/library/papers/3156026 | PubMed |
| 20 | 6,227,281 | Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6227281 | PubMed |
Cited by226
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 666 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,038,474 | Comparative in vitro antibacterial activity of herbal extracts from Piper betle L., Bauhinia scandens L. and Chromolaena odorata against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. | PeerJ | 2026 | https://conductscience.org/library/papers/42038474 | PubMed |
| 41,991,528 | Beyond metabolic dormancy: metabolic rewiring in bacterial persistence. | Nat Commun | 2026 | https://conductscience.org/library/papers/41991528 | PubMed |
| 41,465,289 | Experimental Study and Molecular Modeling of Antibody Interactions with Different Fluoroquinolones. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465289 | PubMed |
| 41,253,746 | Therapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41253746 | PubMed |
| 40,430,428 | Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40430428 | PubMed |
| 40,317,056 | Antibiotic type and dose variably affect microbiomes of a disease-resistant Acropora cervicornis genotype. | Environ Microbiome | 2025 | https://conductscience.org/library/papers/40317056 | PubMed |
| 39,126,607 | Green Approach for Simultaneous Quantitative Analysis of Fluoroquinolones in the Environment using Three-Dimensional Fluorescence Coupled with Second-Order Calibration Method. | J Fluoresc | 2025 | https://conductscience.org/library/papers/39126607 | PubMed |
| 38,045,542 | Contribution of the SOS response and the DNA repair systems to norfloxacin induced mutations in E. coli. | Mar Life Sci Technol | 2023 | https://conductscience.org/library/papers/38045542 | PubMed |
| 37,891,886 | Boswellia Essential Oil: Natural Antioxidant as an Effective Antimicrobial and Anti-Inflammatory Agent. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/37891886 | PubMed |
| 37,754,560 | Efflux pump inhibitory potential of indole derivatives as an arsenal against norA over-expressing Staphylococcus aureus. | Microbiol Spectr | 2023 | https://conductscience.org/library/papers/37754560 | PubMed |
| 37,630,269 | Fluoroquinolone Analogs, SAR Analysis, and the Antimicrobial Evaluation of 7-Benzimidazol-1-yl-fluoroquinolone in In Vitro, In Silico, and In Vivo Models. | Molecules | 2023 | https://conductscience.org/library/papers/37630269 | PubMed |
| 37,247,149 | Metabolic variation and oxidative stress response of blue mussels (Mytilus sp.) perturbed by norfloxacin exposure. | Environ Sci Pollut Res Int | 2023 | https://conductscience.org/library/papers/37247149 | PubMed |
| 36,624,327 | Enrofloxacin Poisoning: A Rare Occurrence in Children. | Indian J Pediatr | 2023 | https://conductscience.org/library/papers/36624327 | PubMed |
| 36,466,935 | Metal-Organic Framework-Based Composites for the Detection and Monitoring of Pharmaceutical Compounds in Biological and Environmental Matrices. | Water Air Soil Pollut | 2022 | https://conductscience.org/library/papers/36466935 | PubMed |
| 36,119,794 | Alhagi maurorum aqueous extract protects against norfloxacin-induced hepato-nephrotoxicity in rats. | Chin Herb Med | 2020 | https://conductscience.org/library/papers/36119794 | PubMed |
| 35,409,007 | Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections? | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35409007 | PubMed |
| 35,283,843 | Interactions Between Intestinal Microbiota and Neural Mitochondria: A New Perspective on Communicating Pathway From Gut to Brain. | Front Microbiol | 2022 | https://conductscience.org/library/papers/35283843 | PubMed |
| 34,908,449 | Enoxacin Shows Broad-Spectrum Antiviral Activity against Diverse Viruses by Enhancing Antiviral RNA Interference in Insects. | J Virol | 2022 | https://conductscience.org/library/papers/34908449 | PubMed |
| 34,703,723 | pH-driven enhancement of anti-tubercular drug loading on iron oxide nanoparticles for drug delivery in macrophages. | Beilstein J Nanotechnol | 2021 | https://conductscience.org/library/papers/34703723 | PubMed |
| 33,652,626 | Characterization of a Novel Variant of the Quinolone-Resistance Gene qnrB (qnrB89) Carried by a Multi-Drug Resistant Citrobacter gillenii Strain Isolated from Farmed Salmon in Chile. | Antibiotics (Basel) | 2021 | https://conductscience.org/library/papers/33652626 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3000292
GET https://conductscience.org/api/papers/v1/3000292/references?page=2